132 related articles for article (PubMed ID: 16108831)
21. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
22. Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis.
Wang J; Yang Y; Xia HH; Gu Q; Lin MC; Jiang B; Peng Y; Li G; An X; Zhang Y; Zhuang Z; Zhang Z; Kung HF; Wong BC
Gastroenterology; 2007 Mar; 132(3):1066-76. PubMed ID: 17383428
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel prostate cancer-associated tumor antigen.
Miles AK; Rogers A; Li G; Seth R; Powe D; McArdle SE; McCulloch TA; Bishop MC; Rees RC
Prostate; 2007 Feb; 67(3):274-87. PubMed ID: 17192878
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.
Kong J; Diao Z; Deng X; Zhong H; Yao W; Hu X
Oncol Rep; 2007 Jul; 18(1):279-85. PubMed ID: 17549380
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
Ishizaki H; Tsunoda T; Wada S; Yamauchi M; Shibuya M; Tahara H
Clin Cancer Res; 2006 Oct; 12(19):5841-9. PubMed ID: 17020992
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients.
Wang Y; Harada M; Yano H; Ogasawara S; Tanaka M; Yamada A; Itoh K
Oncol Rep; 2006 Feb; 15(2):317-21. PubMed ID: 16391848
[TBL] [Abstract][Full Text] [Related]
28. [Possibilities of glypican-3-specific immunotherapy for hepatocellular carcinoma].
Komori H; Nakatsura T; Beppu T; Nishimura Y; Baba H
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1742-4. PubMed ID: 17212093
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice.
Zhang W; Liu J; Wu Y; Xiao F; Wang Y; Wang R; Yang H; Wang G; Yang J; Deng H; Li J; Wen Y; Wei Y
Biochem Biophys Res Commun; 2008 Nov; 376(1):10-4. PubMed ID: 18725206
[TBL] [Abstract][Full Text] [Related]
30. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
Homma S; Harada M; Yano H; Ogasawara S; Shichijo S; Matsueda S; Komatsu N; Shomura H; Maeda Y; Sato Y; Todo S; Itoh K
Int J Oncol; 2006 Sep; 29(3):577-87. PubMed ID: 16865273
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of peptidyl-prolyl isomerase-like 1 is associated with the growth of colon cancer cells.
Obama K; Kato T; Hasegawa S; Satoh S; Nakamura Y; Furukawa Y
Clin Cancer Res; 2006 Jan; 12(1):70-6. PubMed ID: 16397026
[TBL] [Abstract][Full Text] [Related]
32. Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations.
Dakshinamurthy AG; Ramesar R; Goldberg P; Blackburn JM
Biotechnol J; 2008 Nov; 3(11):1417-23. PubMed ID: 18956367
[TBL] [Abstract][Full Text] [Related]
33. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
[TBL] [Abstract][Full Text] [Related]
34. Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target.
Shimokawa T; Matsushima S; Tsunoda T; Tahara H; Nakamura Y; Furukawa Y
Int J Oncol; 2006 Aug; 29(2):381-6. PubMed ID: 16820880
[TBL] [Abstract][Full Text] [Related]
35. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
[TBL] [Abstract][Full Text] [Related]
36. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma.
Nakamura S; Nouso K; Noguchi Y; Higashi T; Ono T; Jungbluth A; Chen YT; Old LJ; Nakayama E; Shiratori Y
J Gastroenterol Hepatol; 2006 Aug; 21(8):1281-5. PubMed ID: 16872310
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
[TBL] [Abstract][Full Text] [Related]
38. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers.
Sakakura C; Hasegawa K; Miyagawa K; Nakashima S; Yoshikawa T; Kin S; Nakase Y; Yazumi S; Yamagishi H; Okanoue T; Chiba T; Hagiwara A
Clin Cancer Res; 2005 Sep; 11(18):6479-88. PubMed ID: 16166423
[TBL] [Abstract][Full Text] [Related]
39. A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers.
Okada T; Akada M; Fujita T; Iwata T; Goto Y; Kido K; Okada T; Matsuzaki Y; Kobayashi K; Matsuno S; Sunamura M; Kawakami Y
Clin Cancer Res; 2006 Jan; 12(1):191-7. PubMed ID: 16397042
[TBL] [Abstract][Full Text] [Related]
40. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
